- |
My Account- |
Janus kinases (JAKs) are non-receptor tyrosine kinases which play the key role in JAK-STAT signaling pathway. A large number of cytokines depend on JAK including interleukin (IL)-2, IL-4, IL-7, IL-9, IL-15 and IL-21. Jak kinases are involved in malignant cell growth and survival. Jak kinases have been shown to modulate activation of Ras-Raf-MAP kinase pathways which are implicated in malignant transformation. The function of Jak kinases is also related to Abl. Jak kinases have been also implicated in the regulation of p53-dependent cell-cycle arrest and apoptosis, for example, Jak kinases can regulate the levels of Bcl-XL, Bcl-2 and Bax expression by their effects on Stats and other receptor linked pathways such as the PI-3 kinase and the Ras-MAPK pathways.
| Cat.No. | Product Name | Information | Publication | Customer Review |
|---|---|---|---|---|
| S5001 | Tofacitinib citrate (CP-690550 citrate) | Tofacitinib citrate (CP-690550) is a potent JAK3 inhibitor with IC50 of 1 nM. |
 (5)
|
 (4)
|
| S2736 | TG101348 (SAR302503) | TG-101348 (SAR302503) is a selective inhibitor of JAK2 with IC50 of 3 nM. |
|
(1)
|
| S2789 | Tofacitinib (CP-690550, Tasocitinib) | CP-690550 is a novel inhibitor of JAK3 with IC50 of 1 nM. |
(11)
|
|
| S2162 | AZD1480 | AZD1480 is a novel ATP-competitive inhibitor of JAK1 and JAK2 with IC50 of 1.3 nM and 0.26 nM, respectively. |
(1)
|
(1)
|
| S1143 | AG-490 | AG-490 (Tyrphostin B42) is an inhibitor of EGFR, ErbB2 and JAK2 with IC50 of 0.1 μM, 13.5 μM, and ~10 μM, respectively. |
(2)
|
|
| S2219 | Cyt387 | CYT387 is an ATP-competitive inhibitor of JAK1 and JAK2 with IC50 of 11 nM and 18 nM, respectively. |
(1)
|
|
| S2686 | NVP-BSK805 | NVP-BSK805 is a potent and selective ATP-competitive JAK2 inhibitor with IC50 of 0.5 nM. |
|
(1)
|
| S8004 | ZM 39923 HCl | ZM39923 is an JAK inhibitor for JAK1, JAK3, EFGR and TGM2 with IC50 of 4.4 μM, 7.1 μM, 5.6 μM and 10 nM, respectively. |
|
|
| S2867 | WHI-P154 | WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM and also inhibits EGFR with IC50 of 4 nM. |
|
|
| S2851 | Baricitinib (LY3009104, INCB28050) | Baricitinib is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, respectively. |
|
|
| S2796 | WP1066 | WP1066 is a novel inhibitor of JAK2 and STAT3 with IC50 of 2.30 μM and 2.43 μM in HEL cells . |
|
|
